Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0IGZRX)
| ADC Name |
PRO-1286
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
PRO-1286; PRO1286; GEN1286
Click to Show/Hide
|
|||||
| Organization |
ProfoundBio (Originator)
|
|||||
| Drug Status |
Phase 1/2 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Anti-EGFR/c-Met bsAb
|
Antibody Info | ||||
| Antigen Name |
Hepatocyte growth factor receptor (MET); Epidermal growth factor receptor (EGFR)
|
Antigen Info | ||||
| Payload Name |
Exatecan
|
Payload Info | ||||
| Payload Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
T1000
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
sesutecan
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Key inclusion criteria: age ≥18; ECOG 0-1; measurable advanced solid tumors (RECIST 1.1); refractory to standard therapies; adequate organ function; willingness to provide tumor samples.
|
||||
| Administration Dosage |
.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06685068 | Clinical Status | PHASE1|||PHASE2 | ||
| Clinical Description | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | ||||
| Primary Endpoint |
Primary endpoints include AE incidence (NCI-CTCAE v5.0) over 3 years 9 months and DLTs during first cycle (21 days) for GEN1286 safety evaluation.
|
||||
| Other Endpoint |
Secondary endpoints comprise efficacy measures (ORR, DCR, PFS, DOR per RECIST 1.1) and PK parameters (AUC, Cmax, Tmax, t1/2, CL, Vz, Ctrough of antibody-conjugated exatecan components) over 2 years 9 months, plus ADA assessment.
|
||||